Pharmaceuticals, Biotechnology and Life Sciences
Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive…
Marks first key milestone for the Civica Rx-Hikma partnership, which is set to supply 14 essential medicines to US hospitals…
THOUSAND OAKS, Ca.–(BUSINESS WIRE)–Dyve Biosciences, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration…
BRIDGEWATER, N.J. & FOUNTAIN RUN, Ky.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and AvKARE Inc. today announced they have entered into…
– Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in…
Synimmune GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, presented results of its first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Merck said Monday that it iwll, through a subsidiary, initiate a tender offer to acquire all outstanding shares of ArQule for nearly $2.7 billion, or for $20 per share in cash.
DUBLIN–(BUSINESS WIRE)–The “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2019” report has been added to…
Equillium got U.S. FDA’s Fast Track designation for itolizumab for the treatment of lupus nephritis, after startign the phase 1 study of itolizumab in patients with lupus and lupus nephritis in September 2019.
LONDON & WALTHAM, Mass.–(BUSINESS WIRE)–Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours…